|
The Journal of Lipid Research, Vol. 39, 1079-1090, May 1998
Copyright © 1998 by Lipid Research, Inc.
Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice
David A. Birda,
Rajendra K. Tangiralaa,
Joachim Fruebisa,
Daniel Steinberga,
Joseph L. Witztuma, and
Wulf Palinskia
a Department of Medicine, University of California, San Diego, La Jolla, CA 92093-0682
Correspondence to:
Wulf Palinski.
Probucol is a powerful inhibitor of atherosclerosis in a number of animal models. However, it is unknown whether this is due to the strong antioxidant protection of low density lipoprotein (LDL), to antioxidant effects in the artery wall, or to cellular effects not shared by other antioxidants. To investigate whether murine models are suitable to study the antiatherogenic mechanisms of probucol, three experiments following different protocols were carried out in 135 male and female LDL receptor-deficient (LDLR-/-) mice. Treatment groups received a high (0.5%) or low (0.025%) dose of probucol, or low-dose probucol plus a high dose (0.1%) of vitamin E for periods ranging from 6 to 26 weeks. In all experiments, probucol strongly protected LDL against ex vivo oxidation (lag times exceeding 1400 min in 0.5% probucol-treated mice). Treatment with 0.5% probucol significantly lowered both HDL-cholesterol and plasma apolipoprotein (apo)A-I concentrations. In all three experiments, treatment with 0.5% probucol consistently increased the size of lesions in the aortic origin, from 1.3-fold (n.s.) to 2.9-fold (P < 0.05) in female mice and from 3.6- to 3.7-fold in males (P < 0.001). Even treatment with 0.025% probucol increased atherosclerosis 1.6-fold in male mice (P < 0.01). Addition of the high dose of vitamin E did not attenuate the pro-atherogenic effect of 0.025% probucol. In conclusion, probucol not only failed to decrease but actively increased atherogenesis in LDLR-/- mice in a dose-dependent manner, even though it provided a very strong antioxidant protection of LDL.
This suggests that the reduction of atherosclerosis observed in other animal models is due to intracellular effects of probucol not found in mice, to differences in the metabolism of probucol, and/or to an overriding atherogenic effect of the decrease in HDL in murine models.Bird, D. A., R. K. Tangirala, J. Fruebis, D. Steinberg, J. L. Witztum, and W. Palinski. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. 1998. 39: 10791090.
Supplementary key words:
modified lipoproteins, oxidation, antioxidants, arteriosclerosis, mice

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Choy, K. Beck, F. Y. Png, B. J. Wu, S. B. Leichtweis, S. R. Thomas, J. Y. Hou, K. D. Croft, T. A. Mori, and R. Stocker
Processes Involved in the Site-Specific Effect of Probucol on Atherosclerosis in Apolipoprotein E Gene Knockout Mice
Arterioscler Thromb Vasc Biol,
August 1, 2005;
25(8):
1684 - 1690.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Stocker and J. F. Keaney Jr.
Role of Oxidative Modifications in Atherosclerosis
Physiol Rev,
October 1, 2004;
84(4):
1381 - 1478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Violi, F. Micheletta, and L. Iuliano
Antioxidants and atherosclerosis
Eur. Heart J. Suppl.,
March 1, 2002;
4(suppl_B):
B17 - B21.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. RICCIARELLI, J.-M. ZINGG, and A. AZZI
Vitamin E: protective role of a Janus molecule
FASEB J,
November 1, 2001;
15(13):
2314 - 2325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Collins, W. P. Meehan, U. Kintscher, S. Jackson, S. Wakino, G. Noh, W. Palinski, W. A. Hsueh, and R. E. Law
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor-Deficient Mice
Arterioscler Thromb Vasc Biol,
March 1, 2001;
21(3):
365 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. K. Witting, K. Pettersson, J. Letters, and R. Stocker
Site-Specific Antiatherogenic Effect of Probucol in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol,
August 1, 2000;
20
(8):
e26 - e33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Parthasarathy, N. Santanam, S. Ramachandran, and O. Meilhac
Oxidants and antioxidants in atherogenesis: an appraisal
J. Lipid Res.,
December 1, 1999;
40(12):
2143 - 2157.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Zuckerman, G. F. Evans, J. A. Schelm, P. I. Eacho, and G. Sandusky
Estrogen-Mediated Increases in LDL Cholesterol and Foam Cell–Containing Lesions in Human ApoB100CETP Transgenic Mice
Arterioscler Thromb Vasc Biol,
June 1, 1999;
19(6):
1476 - 1483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Merat, F. Casanada, M. Sutphin, W. Palinski, and P. D. Reaven
Western-Type Diets Induce Insulin Resistance and Hyperinsulinemia in LDL Receptor-Deficient Mice But Do Not Increase Aortic Atherosclerosis Compared With Normoinsulinemic Mice in Which Similar Plasma Cholesterol Levels Are Achieved by a Fructose-Rich Diet
Arterioscler Thromb Vasc Biol,
May 1, 1999;
19(5):
1223 - 1230.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Moghadasian, B. M. McManus, D. V. Godin, B. Rodrigues, and J. J. Frohlich
Proatherogenic and Antiatherogenic Effects of Probucol and Phytosterols in Apolipoprotein E–Deficient Mice : Possible Mechanisms of Action
Circulation,
April 6, 1999;
99(13):
1733 - 1739.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. K. WITTING, K. PETTERSSON, A.-M. ÖSTLUND-LINDQVIST, C. WESTERLUND, A. W. ERIKSSON, and R. STOCKER
Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice
FASEB J,
April 1, 1999;
13(6):
667 - 675.
[Abstract]
[Full Text]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|